Cadrenal Therapeutics, Inc. Common StockCVKDNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +27.16% | +75.66% | +72.34% | +83.81% | +85.15% |
| Weighted Average Shares Diluted Growth | +27.16% | +75.66% | +72.34% | +83.81% | +85.15% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -49.75% | +18.83% | +12.84% | +9.55% | -12.64% |
| Book Value per Share Growth | -69.32% | -44.94% | -42.72% | -41.42% | -56.71% |
| Debt Growth | -91.80% | -100.00% | -100.00% | -100.00% | -100.00% |
| R&D Expense Growth | +221.64% | +325.79% | +165.15% | -14.06% | -12.26% |
| SG&A Expenses Growth | +86.50% | +203.78% | +100.23% | +119.10% | +22.09% |